vin, not exactly because on the positive side of Bavituximab we HAVE clinical trials that prove Bavituximab worked as expected (said exactly with so many words by PPHM).
You also seem to confuse "working drug" with "approved drug". Roche's revenue maker Avastin failed several clinical trials at a point they wanted to stop it...and then...that one trial and boom.
The Breast, Lung, Pancreatic and Liver trials all showed how Bavituximab increase one of the end-points. And for EACH time that the control arm performed better there is a clear explanation. (Randomizing, dose switching, etc).
That is why I don't have to use the word "LIKELY" when I say bavi works, yet you will have to if you say it does NOT work because it cannot perform as many times as designed (3xbreast, 3xLong, 1x Panc, 1xLiver) and then be said to not work. In that context even the likely is out of place IMO.
Market Data 
Markets 
AI
